ITB-Med LLC
13
4
7
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.8%
4 terminated/withdrawn out of 13 trials
33.3%
-53.2% vs industry average
0%
0 trials in Phase 3/4
150%
3 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study of TCD601 in de Novo Renal Transplant Recipients
Role: lead
A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
Role: lead
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
Role: lead
Siplizumab for Sickle Cell Disease Transplant
Role: collaborator
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
Role: lead
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
Role: lead
Delayed Tolerance Through Mixed Chimerism
Role: collaborator
A Study of SIPLIZUMAB in AILD and LT Patients
Role: collaborator
Tolerance Through Mixed Chimerism (Sip-Tego)
Role: collaborator
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
Role: lead
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
Role: collaborator
A Dose Escalation Study in de Novo Renal Transplantation
Role: lead
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
Role: lead
All 13 trials loaded